Abstract
Breast cancer is the most common cancer diagnosed in women. The present study evaluated the family physicians' (FPs) understanding of adjuvant hormonal therapies for an early breast cancer. FPs were invited to attend teaching workshops on this topic, which utilized a pretest, didactic and interactive teaching, and posttest format. FPs (n = 23) showed an improvement (p < 0.001) in pretest to posttest score. It is clear that, with a targeted teaching, FPs can quickly become more knowledgeable on the topic of hormonal therapies in breast cancer, with the potential of applying this information in their own practice.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Goss P, Ingle J, Martino S et al (2003) A randomized trial of letrozole in post-menopausal women after five years of tamoxifen therapy for early stage breast cancer. N Engl J Med 349:1793–1802
Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in post-menopausal women with primary breast cancer. Intergroup Exemestane Study. N Engl J Med 350:1081–1092
Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in combination) trial after completion of 5 years' adjuvant treatment for cancer. ATAC Trialists' Group. Lancet 365(9453):60–62
Thurlimann B, Keshaviah A, Coates AS et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. Breast International Group (BIG) 1-98 Collaborative Group. N Engl J Med 353:2747–2757
Jakesz R, Jonat W, Gnant M et al (2005) Switching of postmenopausal women with endocrine responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABSCG trial 8 and ARNO 95 trial. Lancet 366:455–462
Boccardo F, Rubagotti A, Guglielmini P, et al. (2006) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian Tamoxifen Anastrozole Study (ITA) Trial. Ann Oncol 17 Suppl 7:vii10–vii14
Trotter T, Railton C, Webster M et al (2007) Acceptance of extended hormonal therapy with letrozole after 5 years of adjuvant tamoxifen in post-menopausal breast cancer patients. Abstract. Breast Cancer Res Treat 106(Suppl 1):S145
Davis D, O’Brien MA, Freemantle N et al (1999) Impact of formal continuing medical education: do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes? JAMA 282:867–874
O’Brien MA, Freemantle N, Oxman AD, et al. (2001) Continuing education meetings and workshops: effects on professional practice and health care outcomes. Cochrane Database Syst Rev, Issue 1. Art. no.: CD002020. doi:10.1002/14651858.CD003030
Davis RS, Bukstein DA, Luskin AT et al (2004) Changing physician prescribing patterns through problem-based learning: an interactive, teleconference case-based education program and review of problem-based learning. Ann Allergy Asthma Immunol 93:237–242
White M, Michaud G, Pachev G et al (2004) Randomized trial of problem-based vs didactic seminars for disseminating evidence-based guidelines on asthma management to primary care physicians. J Contin Educ Health Prof 24:237–243
Fordis M, King JE, Ballantyne CM et al (2005) Comparison of the instructional efficacy of internet-based CME with live interactive CME workshops. JAMA 294(9):1043–1051
Author information
Authors and Affiliations
Corresponding author
Additional information
Received from: University of Calgary, Calgary, AB, Canada
Rights and permissions
About this article
Cite this article
Trotter, T., Webster, M., Railton, C. et al. A Teaching Model for Aromatase Inhibitors After Tamoxifen. J Canc Educ 25, 493–496 (2010). https://doi.org/10.1007/s13187-010-0095-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13187-010-0095-9